On-Demand Programs

Contemporary Considerations in the Efficacy, Safety, and Implementation of Bispecific Antibody Therapy in NHL
This educational program is an interactive, multi-faculty, debate-style program that will discuss the need for bispecific antibodies in the management of non-Hodgkin’s lymphoma (NHL), summarize the current clinical data informing the use of bispecific antibodies, potential adverse events associated with the bispecific antibody therapy in NHL, and the role of multidisciplinary team in the optimal diagnosis, treatment and management of NHL. This program also consists of a video case study, and interviews of a nurse and a patient advocate that will discuss the importance of interdisciplinary care and patient advocacy in the treatment of patients with NHL.
RELEASED DATE: October 10, 2024
EXPIRATION DATE: October 10, 2025

Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin’s Lymphomas: Summarizing Current Efficacy and Safety Data (Podcasts)
Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025